Disease · MONDO_0044889
high grade B-cell lymphoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. high grade B-cell lymphoma. Diseases, record MONDO_0044889. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044889
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs45
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| POLATUZUMAB VEDOTIN | CHEMBL3301582 | Antibody drug conjugate | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| MOSUNETUZUMAB | CHEMBL4297788 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TISAGENLECLEUCEL | CHEMBL3301574 | Cell | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZANUBRUTINIB | CHEMBL3936761 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLOFITAMAB | CHEMBL4298092 | Antibody | Phase 2 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 45
See all 45 drugsTargets66
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 6 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 5 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 4 | B-lymphocyte antigen CD19 binding agent | Phase 3 | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 3 | T cell surface glycoprotein CD3 binding agent | Phase 3 | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 3 | T cell surface glycoprotein CD3 binding agent | Phase 3 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 3 | T cell surface glycoprotein CD3 binding agent | Phase 3 | https://conductscience.org/library/genes/917 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 3 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 66
See all 66 targetsTrials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 3 | 208 | 2026-03-06 | Non-Hodgkin Lymphoma | MOSUNETUZUMAB, POLATUZUMAB VEDOTIN | Its record names the disease | ClinicalTrials.gov |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | 113 | 2024-12-27 | Lymphoma, Non-Hodgkin | LISOCABTAGENE MARALEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Phase 1/2 | 46 | 2024-08-13 | Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma | EPCORITAMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | 41 | 2025-01-30 | Diffuse Large B-cell Lymphoma | LONCASTUXIMAB TESIRINE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Phase 1 | 29 | 2025-04-17 | B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor | ZELENIRSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04313608 | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | Phase 1 | 23 | 2024-03-25 | B-cell Lymphoma | GEMCITABINE, GLOFITAMAB, MOSUNETUZUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | Phase 1/2 | 13 | 2025-03-25 | Non-Hodgkin Lymphoma | NADRAVALEUCEL, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | Phase 1 | 8 | 2024-07-09 | Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB) | COPANLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | 211 | Non-Hodgkins Lymphoma | ATEZOLIZUMAB, GLOFITAMAB, OBINUTUZUMAB, POLATUZUMAB VEDOTIN, ZIRCONIUM ZR-89-DESFERRIOXAMINE-IAB22M2C | Its record names the disease | ClinicalTrials.gov | |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | Phase 3 | 200 | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | TISAGENLECLEUCEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Mosun-Pola vs Arm B: R-GemOx: deaths from any cause | 66 of 135 | 35 of 64 | 199 | NCT05171647 | Trial comparisons |
| Arm A: Mosun-Pola vs Arm B: R-GemOx: serious adverse events | 45 of 135 | 16 of 64 | 199 | NCT05171647 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): Number of Participants With Confirmed Positive Anti-Drug Antibody (ADA) Response | 0 of 17 | 0 of 24 | 41 | NCT05144009 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): deaths from any cause | 5 of 17 | 10 of 24 | 41 | NCT05144009 | Trial comparisons |
| Cohort A: Loncastuximab Tesirine + Rituximab (Lonca-R) vs Cohort B: Loncastuximab Tesirine + Rituximab (Lonca-R): serious adverse events | 13 of 17 | 16 of 24 | 41 | NCT05144009 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: Number of Deaths Due to Adverse Events (AEs) | 1 of 17 | 0 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: Number of Treatment Discontinuations Due to AE | 1 of 17 | 1 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: deaths from any cause | 1 of 17 | 0 of 6 | 23 | NCT04313608 | Trial comparisons |
| Arm A: Glofit-GemOx vs Arm B: Mosun-GemOx: serious adverse events | 12 of 17 | 4 of 6 | 23 | NCT04313608 | Trial comparisons |
| Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib vs Dose Escalation: Arm 1, Dose Level 1, Modified: 30mg Copanlisib: Number of Participants With Dose Limiting-toxicity (DLT) | 2 of 5 | 1 of 3 | 8 | NCT04933617 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 38837078 | RESULT | 1 | PubMed |
| 42971868 | DERIVED | 1 | PubMed |
| 42879743 | DERIVED | 1 | PubMed |
| 42298056 | DERIVED | 1 | PubMed |
| 42283231 | DERIVED | 1 | PubMed |
| 41115257 | DERIVED | 1 | PubMed |
| 41037766 | DERIVED | 1 | PubMed |
| 40674734 | DERIVED | 1 | PubMed |
| 40532125 | DERIVED | 1 | PubMed |
| 39319495 | DERIVED | 1 | PubMed |
1 to 10 of 16
See all 16 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044889
GET https://conductscience.org/api/diseases/v1/MONDO_0044889/drugs?page=2